A Phase I/II trial of NOUS-209 to prevent the occurrence of cancer in Lynch Syndrome Carriers and treating cancer

Trial Profile

A Phase I/II trial of NOUS-209 to prevent the occurrence of cancer in Lynch Syndrome Carriers and treating cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs NOUS-209 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2017 New trial record
    • 06 Nov 2017 According to a NousCom media release, the company is planning to conduct this trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top